ATE301998T1 - Verwendung von isovaleryl-l-carnitin zur herstellung eines arzneimittels zur vorbeugung und therapie von osteoporose - Google Patents
Verwendung von isovaleryl-l-carnitin zur herstellung eines arzneimittels zur vorbeugung und therapie von osteoporoseInfo
- Publication number
- ATE301998T1 ATE301998T1 AT01271219T AT01271219T ATE301998T1 AT E301998 T1 ATE301998 T1 AT E301998T1 AT 01271219 T AT01271219 T AT 01271219T AT 01271219 T AT01271219 T AT 01271219T AT E301998 T1 ATE301998 T1 AT E301998T1
- Authority
- AT
- Austria
- Prior art keywords
- isovaleryl
- carnitine
- osteoporosis
- prevention
- treatment
- Prior art date
Links
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 title abstract 2
- 208000001132 Osteoporosis Diseases 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000001582 osteoblastic effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2000RM000688A IT1317079B1 (it) | 2000-12-21 | 2000-12-21 | Uso della isovaleril l-carnitina per la preparazione di un medicamentoper la prevenzione e cura dell'osteoporosi. |
| PCT/IT2001/000614 WO2002049639A1 (en) | 2000-12-21 | 2001-12-04 | Use of isovaleryl l-carnitine for the preparation of a medicament for the prevention and cure of osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE301998T1 true ATE301998T1 (de) | 2005-09-15 |
Family
ID=11455074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01271219T ATE301998T1 (de) | 2000-12-21 | 2001-12-04 | Verwendung von isovaleryl-l-carnitin zur herstellung eines arzneimittels zur vorbeugung und therapie von osteoporose |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6906102B2 (de) |
| EP (1) | EP1351676B1 (de) |
| AT (1) | ATE301998T1 (de) |
| AU (1) | AU2002217431A1 (de) |
| CA (1) | CA2434962C (de) |
| CZ (1) | CZ304356B6 (de) |
| DE (1) | DE60112802T2 (de) |
| DK (1) | DK1351676T3 (de) |
| ES (1) | ES2247005T3 (de) |
| HU (1) | HU227342B1 (de) |
| IT (1) | IT1317079B1 (de) |
| MX (1) | MXPA03006332A (de) |
| PL (1) | PL207879B1 (de) |
| SK (1) | SK287306B6 (de) |
| WO (1) | WO2002049639A1 (de) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1290801B1 (it) | 1996-07-05 | 1998-12-11 | Mendes Srl | Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili |
| IT1291141B1 (it) * | 1997-04-16 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica comprendente una alcanoil l-carnitina, atta a stimolare la moltiplicazione e la crescita degli osteoblasti |
| IT1299191B1 (it) * | 1998-06-23 | 2000-02-29 | Sigma Tau Healthscience Spa | Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa |
-
2000
- 2000-12-21 IT IT2000RM000688A patent/IT1317079B1/it active
-
2001
- 2001-12-04 EP EP01271219A patent/EP1351676B1/de not_active Expired - Lifetime
- 2001-12-04 MX MXPA03006332A patent/MXPA03006332A/es active IP Right Grant
- 2001-12-04 WO PCT/IT2001/000614 patent/WO2002049639A1/en not_active Ceased
- 2001-12-04 DK DK01271219T patent/DK1351676T3/da active
- 2001-12-04 US US10/470,158 patent/US6906102B2/en not_active Expired - Fee Related
- 2001-12-04 AU AU2002217431A patent/AU2002217431A1/en not_active Abandoned
- 2001-12-04 HU HU0400735A patent/HU227342B1/hu not_active IP Right Cessation
- 2001-12-04 CZ CZ2003-1890A patent/CZ304356B6/cs not_active IP Right Cessation
- 2001-12-04 AT AT01271219T patent/ATE301998T1/de active
- 2001-12-04 CA CA2434962A patent/CA2434962C/en not_active Expired - Fee Related
- 2001-12-04 SK SK891-2003A patent/SK287306B6/sk not_active IP Right Cessation
- 2001-12-04 ES ES01271219T patent/ES2247005T3/es not_active Expired - Lifetime
- 2001-12-04 DE DE60112802T patent/DE60112802T2/de not_active Expired - Lifetime
- 2001-12-04 PL PL367293A patent/PL207879B1/pl unknown
-
2005
- 2005-01-11 US US11/032,019 patent/US7084174B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ITRM20000688A1 (it) | 2002-06-21 |
| HUP0400735A3 (en) | 2009-01-28 |
| DE60112802D1 (de) | 2005-09-22 |
| PL367293A1 (en) | 2005-02-21 |
| ES2247005T3 (es) | 2006-03-01 |
| HU227342B1 (en) | 2011-04-28 |
| WO2002049639A1 (en) | 2002-06-27 |
| US7084174B2 (en) | 2006-08-01 |
| ITRM20000688A0 (it) | 2000-12-21 |
| IT1317079B1 (it) | 2003-05-26 |
| EP1351676A1 (de) | 2003-10-15 |
| US20040077718A1 (en) | 2004-04-22 |
| CZ304356B6 (cs) | 2014-03-26 |
| EP1351676B1 (de) | 2005-08-17 |
| SK287306B6 (sk) | 2010-06-07 |
| DK1351676T3 (da) | 2005-12-19 |
| HUP0400735A2 (hu) | 2004-07-28 |
| CA2434962A1 (en) | 2002-06-27 |
| MXPA03006332A (es) | 2004-04-21 |
| DE60112802T2 (de) | 2006-03-16 |
| PL207879B1 (pl) | 2011-02-28 |
| CA2434962C (en) | 2010-02-09 |
| US20050143458A1 (en) | 2005-06-30 |
| CZ20031890A3 (cs) | 2004-04-14 |
| SK8912003A3 (en) | 2003-11-04 |
| US6906102B2 (en) | 2005-06-14 |
| AU2002217431A1 (en) | 2002-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE330593T1 (de) | Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen | |
| DE69934813D1 (de) | Verwendung von gaba analogen zur herstellung eines arzneimittels zur behandlung von manie und bipolaren erkrankungen | |
| DE3684190D1 (de) | Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. | |
| DE60015392D1 (de) | Verwendung von annexin-modulatoren zur herstellung eines medikaments zur behandlung und/oder vorbeugung von arthritis und arthritischen erkrankungen | |
| DE69636343D1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
| ATE231885T1 (de) | Verwendung von komplement-inhibitoren zur herstellung eines arzneimittels zur prophylaxe und therapie von entzündlichen darm- und hauterkrankungen sowie purpura | |
| ATE230985T1 (de) | Verwendung von xanthophyllen zur herstellung von arzneimitteln zur verbesserung der muskel- funktionsdauer oder zur behandlung von muskelstörungen oder erkrankungen | |
| DE59907752D1 (de) | Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien | |
| ATE299022T1 (de) | Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis | |
| DE69713620D1 (de) | Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia | |
| DE69331605D1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
| ATE269077T1 (de) | Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen | |
| ATE353645T1 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
| ATE206914T1 (de) | Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen | |
| ATE187329T1 (de) | Carnitinderivat als arzneimittel zur behandlung von arteriosklerose obliterans | |
| DE69637449D1 (de) | Verwendung von alpha-hydroxysäuren zur herstellung eines arzneimittels für die behandlung von entzündungen | |
| ATE246518T1 (de) | Egr-1 zur herstellung eines medikamentes zur behandlung von wunden | |
| ATE311866T1 (de) | Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln zur behandlung von erkrankungen rheumatischer natur | |
| ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| DE3686520D1 (de) | Verwendung von einigen alkanoyl-l-carnitinen zur herstellung eines arzneimittels zur therapeutischen behandlung von ideopathischem oder induziertem parkinsonismus. | |
| DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| DE60128911D1 (de) | Verwendung von l-threo-methylphenidat zur herstellung eines medikamentes zur behandlung von psychischen erkrankungen | |
| ATE192929T1 (de) | Verwendung von dimeticon zur herstellung eines arzneimittels zur behandlung von aphthen und stomatitis | |
| ATE301998T1 (de) | Verwendung von isovaleryl-l-carnitin zur herstellung eines arzneimittels zur vorbeugung und therapie von osteoporose | |
| NZ334571A (en) | Pharmaceutical composition comprising 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy-acetic acid for treating diseases induced by respiratory syncytial virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1351676 Country of ref document: EP |